Literature DB >> 680792

The effects of oral D-penicillamine treatment on experimental arthritis and the associated immune response in rabbits.

I M Hunneyball, G A Stewart, D R Stanworth.   

Abstract

D-penicillamine given orally to rabbits at a dose of 15 mg/kg body weight, administered daily for long periods commencing prior to and at the time of immunization, reduced the concentration of specific IgG antibodies directed against ovalbumin. This effect was not observed when treatment with the drug commenced after immunization and the onset of a mono-articular arthritis. The concentration of serum IgA rose abruptly after antigen was injected intra-articularly to induce the arthritis. This increase was not affected by treatment with D-penicillamine. The concentration of serum IgA decreased markedly during the chronic phase of the mono-articular arthritis, falling below the lower limit of the normal range. Treatment with D-penicillamine for at least 50 days restored the serum IgA concentration to the middle of the normal range. D-penicillamine treatment had no significant effect on the concentration of IgG, or IgM in serum either before or after the onset of mono-articular arthritis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 680792      PMCID: PMC1457410     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  13 in total

1.  SUPPRESSION OF THE PRIMARY IMMUNE RESPONSE INDUCED BY D-L PENICILLAMINE.

Authors:  K ALTMAN; M S TOBIN
Journal:  Proc Soc Exp Biol Med       Date:  1965-02

2.  DEPRESSION OF THE PRIMARY IMMUNE RESPONSE BY DL-PENICILLAMINE.

Authors:  K F HUEBNER; N GENGOZIAN
Journal:  Proc Soc Exp Biol Med       Date:  1965-02

3.  The production of arthritis in rabbits by an immunological reaction to fibrin.

Authors:  D C DUMONDE; L E GLYNN
Journal:  Br J Exp Pathol       Date:  1962-08

4.  Intra-articular dissociation of the rheumatoid factor.

Authors:  I A JAFFE
Journal:  J Lab Clin Med       Date:  1962-09

5.  ACCELERATED IMMUNE RESPONSE INDUCED BY D-L PENICILLAMINE.

Authors:  M S TOBIN; K ALTMAN
Journal:  Proc Soc Exp Biol Med       Date:  1964-01

6.  Effect of D(-)penicillamine on chronic experimental arthritis in rabbits.

Authors:  I M Hunneyball; G A Stewart; D R Stanworth
Journal:  Ann Rheum Dis       Date:  1977-08       Impact factor: 19.103

7.  Failure of oral D-penicillamine to modify adjuvant arthritis or immune response in the rat.

Authors:  S P Liyanage; H L Currey
Journal:  Ann Rheum Dis       Date:  1972-11       Impact factor: 19.103

8.  Further studies on single radial immunodiffusion. II. The reversed system: diffusion of antibodies in antigen-containing gels.

Authors:  J P Vaerman; A M Lebacq-Verheyden; L Scolari; J F Heremans
Journal:  Immunochemistry       Date:  1969-03

9.  Deficient IgA antibody responses to arsanilic acid bovine serum albumin (BSA) in neonatally thymectomized rabbits.

Authors:  J D Clough; L H Mims; W Strober
Journal:  J Immunol       Date:  1971-06       Impact factor: 5.422

10.  Penicillamine in rheumatoid disease: a long-term study.

Authors:  A T Day; J R Golding; P N Lee; A D Butterworth
Journal:  Br Med J       Date:  1974-02-02
View more
  4 in total

1.  IgA-alpha 1 antitrypsin complexes in ankylosing spondylitis.

Authors:  G R Struthers; I V Lewin; D R Stanworth
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

2.  Antibody producing capacity to the bacteriophage phi X174 in rheumatoid arthritis.

Authors:  R Bucknall; P Bacon; C Elson; J V Jones
Journal:  Ann Rheum Dis       Date:  1987-12       Impact factor: 19.103

3.  Effect of oral D-penicillamine treatment on experimental arthritis and associated immune responses in rabbits. III: Reduction of the monoarticular arthritis.

Authors:  I M Hunneyball; G A Stewart; D R Stanworth
Journal:  Ann Rheum Dis       Date:  1979-06       Impact factor: 19.103

4.  Inhibition of human helper T cell function in vitro by D-penicillamine and CuSO4.

Authors:  P E Lipsky; M Ziff
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.